COVAX Manufacturing Taskforce: Achievements and Challenges Ahead

Melanie Saville
CEPI, Director of Vaccine Research and Development
Support COVAX mission to end acute phase of the pandemic by end 2021

Optimise the number of vaccine doses manufactured in the short term

Prioritise doses for COVAX with a special emphasis on AMC92 to ensure greater equity

Mitigate unintended impact on other vaccines and health products

Initiate regional health security through establishment of sustainable regional long-term manufacturing of vaccines
# Manufacturing Taskforce Accomplishments

## Workstream 1 – Immediate COVAX Response

<table>
<thead>
<tr>
<th>Activity</th>
<th>Accomplishments</th>
</tr>
</thead>
</table>
| Supply Chain Efficiency | ✓ Launched COVAX Marketplace July 2021  
  ✓ Onboarded 17 partner suppliers and manufacturers  
  ✓ Completed two matches resulting in ~78M vaccine doses  
  ✓ Engaged with 30 additional partners |
| Free Flow of Goods      | ✓ Support of WTO engagements (e.g., Ministerial Conference, trade investment discussions, etc.)  
  ✓ Raised awareness of supplies and criticality of access |

## Workstream 2 – Mid-Term COVAX Response

<table>
<thead>
<tr>
<th>Activity</th>
<th>Accomplishments</th>
</tr>
</thead>
</table>
| Fill & Finish Matchmaking | ✓ Completed analysis of single dose vs. multidose vials and impact to vaccine availability and supply  
  ✓ Transitioned upgrade of F&F match-making to within the COVAX Marketplace |
| Workforce Development     | ✓ Completed analysis of workforce development needs via interviews with industry associations, vaccine manufacturers and training org; identified longer-term need and transitioned to Workstream 3  
  ✓ Travel restrictions and priority immunization of critical workforce resolved as vaccines more available worldwide |

## Workstream 3 – Long-Term Sustainable Manufacturing

<table>
<thead>
<tr>
<th>Activity</th>
<th>Accomplishments</th>
</tr>
</thead>
</table>
| South Africa mRNA Hub     | ✓ Letter of Intent signed to established Hub signed 30 July  
  ✓ Successfully held field trip to South Africa 6-9 September – milestones and baseline budgets established  
  ✓ Conducted funders’ meeting 22 September |
Manufacturing Taskforce WS3

WS3 ambition is to improve long-term LMIC health security via two key objectives and enablers

1. **Objective 1**
   Expand capabilities of existing manufacturers in LMICs

2. **Objective 2**
   Establish sustainable capacity in regions with no significant capacity

**Enablers**
Identify & implement innovations and develop normative frameworks
## Workstream 3 – Sustainable Manufacturing: Near-Term Priorities

<table>
<thead>
<tr>
<th>Working Groups</th>
<th>Priority</th>
</tr>
</thead>
</table>
| 1/ Tech Innovation, Selection & IP | • Select early-stage tech donors to develop local Covid mRNA vaccine  
• Issue call for expression of interest to receive training at the Hub |
| 2/ Product dev., Manufacturing & Plants | • Assess product development needs for SA hub |
| 3/ Regulatory & Clinical Dev. | • Support clinical development for mRNA techs |
| 4/ Business Model & Financing | • Finalize demand / offer mapping to assess need for additional capacity |
| 5/ Funding & Governance | • Follow up on conversations with potential funders |
| 6/ Workforce development | • Identify potential trainers & initiate training  
• Issue a call for expression of interest to host workforce training hub |